Adit Ginde
Concepts (629)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 89 | 2025 | 2069 | 8.440 |
Why?
| | Outpatients | 17 | 2025 | 396 | 5.210 |
Why?
| | Sepsis | 21 | 2024 | 617 | 4.070 |
Why?
| | Critical Illness | 24 | 2025 | 811 | 4.060 |
Why?
| | Hospitalization | 55 | 2025 | 2199 | 3.840 |
Why?
| | Vitamin D | 22 | 2025 | 397 | 3.390 |
Why?
| | Vitamin D Deficiency | 14 | 2021 | 186 | 2.790 |
Why?
| | Intubation, Intratracheal | 19 | 2025 | 257 | 2.470 |
Why?
| | Adult | 166 | 2025 | 37929 | 2.390 |
Why?
| | Emergency Medical Services | 15 | 2025 | 552 | 2.300 |
Why?
| | Influenza, Human | 16 | 2025 | 622 | 2.290 |
Why?
| | Humans | 296 | 2025 | 137585 | 2.270 |
Why?
| | Emergency Medicine | 13 | 2023 | 226 | 2.260 |
Why?
| | Wounds and Injuries | 10 | 2025 | 758 | 2.250 |
Why?
| | Cholecalciferol | 7 | 2024 | 60 | 2.250 |
Why?
| | Aged | 119 | 2025 | 23961 | 2.230 |
Why?
| | Hyperoxia | 4 | 2023 | 90 | 2.210 |
Why?
| | Hospital Mortality | 21 | 2025 | 911 | 2.150 |
Why?
| | Physician Assistants | 7 | 2014 | 94 | 2.110 |
Why?
| | Patient Discharge | 11 | 2022 | 897 | 2.090 |
Why?
| | Middle Aged | 142 | 2025 | 33479 | 2.080 |
Why?
| | Laryngoscopy | 10 | 2025 | 109 | 2.060 |
Why?
| | Antibodies, Monoclonal | 11 | 2025 | 1430 | 2.040 |
Why?
| | Length of Stay | 21 | 2025 | 1215 | 2.030 |
Why?
| | Antibodies, Neutralizing | 9 | 2025 | 286 | 1.970 |
Why?
| | United States | 96 | 2025 | 14841 | 1.940 |
Why?
| | Oxygen | 12 | 2025 | 931 | 1.920 |
Why?
| | Influenza Vaccines | 14 | 2025 | 539 | 1.890 |
Why?
| | Laryngoscopes | 9 | 2025 | 38 | 1.860 |
Why?
| | Respiration, Artificial | 11 | 2024 | 645 | 1.830 |
Why?
| | Male | 168 | 2025 | 67762 | 1.740 |
Why?
| | Ritonavir | 3 | 2023 | 74 | 1.740 |
Why?
| | Respiratory Tract Infections | 8 | 2025 | 390 | 1.720 |
Why?
| | Hospitals | 9 | 2023 | 691 | 1.650 |
Why?
| | Antiviral Agents | 9 | 2025 | 744 | 1.610 |
Why?
| | Patient Transfer | 5 | 2015 | 176 | 1.590 |
Why?
| | Female | 165 | 2025 | 73304 | 1.580 |
Why?
| | Health Services Accessibility | 11 | 2019 | 986 | 1.410 |
Why?
| | Oxygen Inhalation Therapy | 5 | 2025 | 157 | 1.380 |
Why?
| | Patient Readmission | 5 | 2022 | 697 | 1.370 |
Why?
| | Antibodies, Viral | 8 | 2025 | 625 | 1.360 |
Why?
| | Vitamins | 8 | 2025 | 185 | 1.300 |
Why?
| | Cross-Sectional Studies | 35 | 2025 | 5472 | 1.290 |
Why?
| | Adenosine Monophosphate | 4 | 2024 | 66 | 1.260 |
Why?
| | Aged, 80 and over | 37 | 2025 | 7635 | 1.260 |
Why?
| | Retrospective Studies | 45 | 2025 | 15657 | 1.260 |
Why?
| | Alanine | 4 | 2024 | 152 | 1.230 |
Why?
| | Health Care Rationing | 2 | 2024 | 59 | 1.200 |
Why?
| | Adolescent | 65 | 2025 | 21513 | 1.190 |
Why?
| | Patient Admission | 7 | 2017 | 197 | 1.190 |
Why?
| | Nursing Homes | 3 | 2015 | 181 | 1.150 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 360 | 1.130 |
Why?
| | Intensive Care Units | 8 | 2025 | 827 | 1.120 |
Why?
| | Rural Health Services | 8 | 2020 | 128 | 1.080 |
Why?
| | Young Adult | 47 | 2025 | 13209 | 1.070 |
Why?
| | Physicians | 10 | 2023 | 910 | 1.050 |
Why?
| | Medicaid | 4 | 2015 | 435 | 1.030 |
Why?
| | Airway Management | 3 | 2024 | 52 | 1.030 |
Why?
| | Health Care Surveys | 17 | 2020 | 565 | 1.030 |
Why?
| | Pneumonia | 5 | 2021 | 639 | 1.010 |
Why?
| | Diabetes Mellitus | 7 | 2024 | 1040 | 0.970 |
Why?
| | Stroke | 6 | 2025 | 1120 | 0.960 |
Why?
| | Nurse Practitioners | 4 | 2012 | 138 | 0.950 |
Why?
| | Treatment Outcome | 34 | 2025 | 10811 | 0.950 |
Why?
| | Vaccination | 20 | 2025 | 1381 | 0.940 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 39 | 0.940 |
Why?
| | Mass Screening | 7 | 2012 | 1287 | 0.910 |
Why?
| | Referral and Consultation | 6 | 2022 | 786 | 0.900 |
Why?
| | Insurance, Health | 5 | 2020 | 283 | 0.870 |
Why?
| | Shock, Traumatic | 1 | 2023 | 14 | 0.810 |
Why?
| | Medically Uninsured | 3 | 2014 | 130 | 0.810 |
Why?
| | Military Personnel | 4 | 2023 | 544 | 0.810 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 128 | 0.800 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2022 | 16 | 0.760 |
Why?
| | Health Services Needs and Demand | 3 | 2013 | 273 | 0.750 |
Why?
| | Minority Groups | 2 | 2023 | 266 | 0.750 |
Why?
| | Brain Ischemia | 4 | 2025 | 338 | 0.740 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 55 | 0.740 |
Why?
| | Internship and Residency | 8 | 2023 | 1147 | 0.720 |
Why?
| | Pneumonia, Viral | 6 | 2020 | 373 | 0.710 |
Why?
| | Coronavirus Infections | 6 | 2020 | 364 | 0.710 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 259 | 0.700 |
Why?
| | Asthma | 11 | 2012 | 2295 | 0.700 |
Why?
| | Primary Health Care | 6 | 2019 | 1738 | 0.700 |
Why?
| | Prospective Studies | 24 | 2025 | 7604 | 0.690 |
Why?
| | Patient Outcome Assessment | 2 | 2021 | 131 | 0.680 |
Why?
| | Double-Blind Method | 18 | 2025 | 1993 | 0.680 |
Why?
| | Age Factors | 13 | 2025 | 3295 | 0.660 |
Why?
| | Acute Kidney Injury | 6 | 2025 | 815 | 0.660 |
Why?
| | Career Choice | 3 | 2010 | 219 | 0.650 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 87 | 0.650 |
Why?
| | Resuscitation Orders | 2 | 2019 | 44 | 0.640 |
Why?
| | Pandemics | 11 | 2023 | 1639 | 0.640 |
Why?
| | Personnel Selection | 2 | 2010 | 78 | 0.630 |
Why?
| | Tracheostomy | 1 | 2021 | 133 | 0.630 |
Why?
| | Critical Care | 5 | 2022 | 601 | 0.630 |
Why?
| | Randomized Controlled Trials as Topic | 15 | 2025 | 1477 | 0.630 |
Why?
| | Warfare | 1 | 2019 | 68 | 0.620 |
Why?
| | Cohort Studies | 18 | 2025 | 5742 | 0.620 |
Why?
| | Spine | 1 | 2021 | 173 | 0.620 |
Why?
| | Machine Learning | 1 | 2024 | 493 | 0.610 |
Why?
| | Translating | 2 | 2010 | 43 | 0.610 |
Why?
| | Hypoxia | 7 | 2025 | 1112 | 0.610 |
Why?
| | Dietary Supplements | 8 | 2025 | 561 | 0.610 |
Why?
| | Resuscitation | 1 | 2021 | 251 | 0.610 |
Why?
| | Point-of-Care Systems | 4 | 2025 | 167 | 0.600 |
Why?
| | Triage | 3 | 2020 | 222 | 0.590 |
Why?
| | Severity of Illness Index | 12 | 2024 | 2828 | 0.580 |
Why?
| | Conservative Treatment | 1 | 2018 | 33 | 0.580 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2025 | 148 | 0.580 |
Why?
| | Acute Disease | 11 | 2025 | 1007 | 0.570 |
Why?
| | Communication Barriers | 2 | 2010 | 104 | 0.570 |
Why?
| | Anxiety | 1 | 2025 | 1035 | 0.560 |
Why?
| | Brain Injuries | 1 | 2023 | 494 | 0.550 |
Why?
| | Health Surveys | 4 | 2014 | 514 | 0.540 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2025 | 45 | 0.540 |
Why?
| | Guideline Adherence | 6 | 2022 | 556 | 0.530 |
Why?
| | Interdisciplinary Studies | 1 | 2016 | 27 | 0.520 |
Why?
| | Financing, Organized | 1 | 2016 | 35 | 0.520 |
Why?
| | Hydroxychloroquine | 3 | 2022 | 58 | 0.520 |
Why?
| | Professional Autonomy | 2 | 2014 | 30 | 0.520 |
Why?
| | Sex Factors | 10 | 2019 | 2071 | 0.520 |
Why?
| | Obesity | 4 | 2022 | 2992 | 0.510 |
Why?
| | Skilled Nursing Facilities | 2 | 2016 | 141 | 0.510 |
Why?
| | Orthopedics | 1 | 2018 | 144 | 0.500 |
Why?
| | Language | 2 | 2010 | 292 | 0.500 |
Why?
| | MicroRNAs | 3 | 2017 | 692 | 0.500 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 255 | 0.500 |
Why?
| | Surveys and Questionnaires | 11 | 2025 | 5778 | 0.500 |
Why?
| | Databases, Factual | 10 | 2021 | 1357 | 0.490 |
Why?
| | Home Care Services | 2 | 2016 | 257 | 0.490 |
Why?
| | Communication | 2 | 2014 | 879 | 0.480 |
Why?
| | Boston | 8 | 2010 | 91 | 0.480 |
Why?
| | Colorado | 10 | 2025 | 4565 | 0.480 |
Why?
| | Multiple Trauma | 1 | 2016 | 100 | 0.470 |
Why?
| | Emergencies | 3 | 2015 | 164 | 0.470 |
Why?
| | Healthcare Disparities | 3 | 2012 | 654 | 0.470 |
Why?
| | Insurance Coverage | 3 | 2016 | 230 | 0.460 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2025 | 36 | 0.460 |
Why?
| | Pilot Projects | 7 | 2023 | 1710 | 0.460 |
Why?
| | Homes for the Aged | 1 | 2015 | 34 | 0.460 |
Why?
| | Hyperglycemia | 2 | 2009 | 347 | 0.450 |
Why?
| | Calcitriol | 3 | 2025 | 58 | 0.450 |
Why?
| | Cross Infection | 2 | 2020 | 256 | 0.450 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 112 | 0.450 |
Why?
| | Halfway Houses | 1 | 2014 | 2 | 0.450 |
Why?
| | Acute Lung Injury | 3 | 2025 | 287 | 0.450 |
Why?
| | Shock, Septic | 4 | 2018 | 219 | 0.430 |
Why?
| | Electronic Health Records | 4 | 2024 | 1069 | 0.430 |
Why?
| | Risk Factors | 15 | 2025 | 10388 | 0.430 |
Why?
| | Organ Dysfunction Scores | 3 | 2024 | 48 | 0.430 |
Why?
| | Nutrition Surveys | 6 | 2011 | 266 | 0.420 |
Why?
| | Patient Compliance | 3 | 2008 | 581 | 0.420 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 93 | 0.420 |
Why?
| | Renin-Angiotensin System | 2 | 2025 | 85 | 0.420 |
Why?
| | Faculty, Medical | 1 | 2016 | 283 | 0.420 |
Why?
| | Betacoronavirus | 3 | 2020 | 270 | 0.410 |
Why?
| | Hospitals, Rural | 2 | 2010 | 39 | 0.410 |
Why?
| | Urban Health Services | 5 | 2020 | 63 | 0.410 |
Why?
| | Positive-Pressure Respiration | 3 | 2025 | 80 | 0.410 |
Why?
| | Time Factors | 16 | 2025 | 6828 | 0.410 |
Why?
| | Hypoglycemia | 2 | 2008 | 445 | 0.410 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 515 | 0.400 |
Why?
| | California | 5 | 2019 | 431 | 0.400 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2025 | 1329 | 0.390 |
Why?
| | International Educational Exchange | 1 | 2012 | 12 | 0.390 |
Why?
| | Logistic Models | 8 | 2024 | 2074 | 0.390 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1000 | 0.390 |
Why?
| | Medicare | 3 | 2015 | 773 | 0.390 |
Why?
| | International Classification of Diseases | 2 | 2014 | 135 | 0.380 |
Why?
| | Renal Dialysis | 1 | 2016 | 435 | 0.380 |
Why?
| | Health Resources | 1 | 2013 | 120 | 0.380 |
Why?
| | Odds Ratio | 6 | 2018 | 1070 | 0.380 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 351 | 0.380 |
Why?
| | Clinical Trials as Topic | 4 | 2024 | 1050 | 0.380 |
Why?
| | Treatment Failure | 6 | 2022 | 356 | 0.380 |
Why?
| | Oximetry | 2 | 2023 | 96 | 0.370 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 804 | 0.370 |
Why?
| | Multivariate Analysis | 6 | 2016 | 1509 | 0.370 |
Why?
| | Observation | 1 | 2011 | 50 | 0.360 |
Why?
| | Patient Education as Topic | 4 | 2010 | 766 | 0.360 |
Why?
| | Hospital Units | 1 | 2011 | 29 | 0.360 |
Why?
| | Military Medicine | 2 | 2022 | 63 | 0.360 |
Why?
| | Case-Control Studies | 13 | 2025 | 3556 | 0.360 |
Why?
| | Liability, Legal | 1 | 2011 | 44 | 0.360 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2011 | 12 | 0.360 |
Why?
| | Inflammation Mediators | 1 | 2014 | 513 | 0.360 |
Why?
| | Appointments and Schedules | 1 | 2011 | 89 | 0.360 |
Why?
| | Malpractice | 1 | 2011 | 46 | 0.350 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2691 | 0.350 |
Why?
| | Biomarkers | 11 | 2025 | 4149 | 0.350 |
Why?
| | Ambulatory Care | 5 | 2023 | 546 | 0.350 |
Why?
| | Patient Safety | 2 | 2016 | 314 | 0.350 |
Why?
| | South Africa | 4 | 2025 | 222 | 0.340 |
Why?
| | Influenza B virus | 3 | 2025 | 44 | 0.340 |
Why?
| | Training Support | 1 | 2010 | 35 | 0.340 |
Why?
| | Parathyroid Hormone | 1 | 2011 | 108 | 0.340 |
Why?
| | Inpatients | 2 | 2021 | 500 | 0.340 |
Why?
| | Personnel, Hospital | 2 | 2020 | 30 | 0.340 |
Why?
| | Interleukin-6 | 2 | 2025 | 778 | 0.340 |
Why?
| | Multicenter Studies as Topic | 5 | 2023 | 310 | 0.330 |
Why?
| | Digital Rectal Examination | 1 | 2010 | 10 | 0.330 |
Why?
| | Occult Blood | 1 | 2010 | 34 | 0.330 |
Why?
| | Blood Glucose | 3 | 2008 | 2186 | 0.320 |
Why?
| | Patient Care | 1 | 2010 | 111 | 0.320 |
Why?
| | Ambulances | 3 | 2023 | 51 | 0.320 |
Why?
| | Inflammation | 1 | 2021 | 2837 | 0.320 |
Why?
| | Child | 22 | 2024 | 21935 | 0.310 |
Why?
| | Risk Assessment | 8 | 2021 | 3457 | 0.310 |
Why?
| | Intrauterine Devices | 1 | 2009 | 31 | 0.310 |
Why?
| | Urban Population | 4 | 2025 | 479 | 0.300 |
Why?
| | Seasons | 7 | 2025 | 547 | 0.300 |
Why?
| | Cause of Death | 2 | 2017 | 434 | 0.290 |
Why?
| | Atracurium | 2 | 2019 | 14 | 0.290 |
Why?
| | Bias | 3 | 2024 | 218 | 0.290 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2019 | 26 | 0.290 |
Why?
| | Socioeconomic Factors | 5 | 2015 | 1289 | 0.280 |
Why?
| | Mathematics | 1 | 2008 | 103 | 0.280 |
Why?
| | Body Mass Index | 4 | 2019 | 2389 | 0.280 |
Why?
| | Registries | 4 | 2024 | 2035 | 0.270 |
Why?
| | Video Recording | 6 | 2025 | 180 | 0.270 |
Why?
| | Immunization, Passive | 2 | 2025 | 90 | 0.270 |
Why?
| | Medical Futility | 2 | 2024 | 23 | 0.270 |
Why?
| | Age Distribution | 4 | 2014 | 392 | 0.260 |
Why?
| | Noninvasive Ventilation | 2 | 2025 | 51 | 0.260 |
Why?
| | Influenza A virus | 2 | 2025 | 107 | 0.260 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4295 | 0.260 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 1040 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3566 | 0.250 |
Why?
| | Ivermectin | 2 | 2023 | 13 | 0.250 |
Why?
| | Data Collection | 4 | 2014 | 673 | 0.250 |
Why?
| | Decision Support Systems, Clinical | 2 | 2021 | 226 | 0.250 |
Why?
| | Crush Injuries | 1 | 2025 | 12 | 0.240 |
Why?
| | Emergency Treatment | 3 | 2019 | 118 | 0.240 |
Why?
| | Calcifediol | 1 | 2025 | 33 | 0.240 |
Why?
| | Oseltamivir | 1 | 2025 | 12 | 0.240 |
Why?
| | Prochlorperazine | 1 | 2025 | 7 | 0.240 |
Why?
| | Prevalence | 6 | 2014 | 2734 | 0.240 |
Why?
| | Community-Acquired Infections | 2 | 2020 | 174 | 0.240 |
Why?
| | Vasoconstrictor Agents | 3 | 2024 | 139 | 0.240 |
Why?
| | Wound Infection | 1 | 2025 | 32 | 0.230 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 383 | 0.230 |
Why?
| | Point-of-Care Testing | 1 | 2025 | 32 | 0.230 |
Why?
| | Renin | 1 | 2024 | 35 | 0.230 |
Why?
| | Oxazines | 1 | 2024 | 30 | 0.230 |
Why?
| | Pregnancy Complications | 1 | 2010 | 527 | 0.230 |
Why?
| | Hospitals, Urban | 3 | 2016 | 134 | 0.220 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.220 |
Why?
| | Cyclopropanes | 1 | 2024 | 90 | 0.220 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 400 | 0.220 |
Why?
| | Glycocalyx | 1 | 2024 | 27 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 119 | 0.220 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2024 | 104 | 0.220 |
Why?
| | Glycine | 1 | 2025 | 176 | 0.220 |
Why?
| | Medical Audit | 2 | 2018 | 78 | 0.220 |
Why?
| | Choice Behavior | 2 | 2019 | 170 | 0.220 |
Why?
| | Acetates | 1 | 2024 | 99 | 0.220 |
Why?
| | Ambulatory Care Facilities | 3 | 2020 | 232 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.220 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 548 | 0.220 |
Why?
| | Fluid Therapy | 2 | 2023 | 147 | 0.220 |
Why?
| | Heart Arrest | 2 | 2025 | 339 | 0.210 |
Why?
| | Incidence | 4 | 2025 | 2804 | 0.210 |
Why?
| | Sulfides | 1 | 2024 | 99 | 0.210 |
Why?
| | Chronic Disease | 3 | 2022 | 1793 | 0.210 |
Why?
| | Diabetic Ketoacidosis | 1 | 2006 | 201 | 0.210 |
Why?
| | Hypotension | 2 | 2023 | 122 | 0.210 |
Why?
| | Altitude Sickness | 1 | 2025 | 153 | 0.210 |
Why?
| | Multiple Organ Failure | 1 | 2024 | 128 | 0.210 |
Why?
| | Disease Progression | 5 | 2021 | 2757 | 0.210 |
Why?
| | Child, Preschool | 12 | 2019 | 11074 | 0.210 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.210 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 278 | 0.210 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 1809 | 0.210 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2023 | 25 | 0.210 |
Why?
| | Quinolines | 1 | 2024 | 178 | 0.200 |
Why?
| | Androstadienes | 1 | 2023 | 107 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 2 | 2020 | 806 | 0.200 |
Why?
| | Immunocompromised Host | 2 | 2022 | 202 | 0.200 |
Why?
| | Electronics | 1 | 2023 | 76 | 0.200 |
Why?
| | Comorbidity | 4 | 2021 | 1622 | 0.200 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 125 | 0.200 |
Why?
| | Lopinavir | 1 | 2022 | 30 | 0.200 |
Why?
| | RNA, Messenger | 7 | 2023 | 2833 | 0.200 |
Why?
| | Blood Transfusion | 1 | 2025 | 325 | 0.200 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 74 | 0.200 |
Why?
| | Violence | 1 | 2025 | 266 | 0.200 |
Why?
| | Plasma | 1 | 2024 | 212 | 0.200 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 1171 | 0.190 |
Why?
| | Recovery of Function | 3 | 2022 | 653 | 0.190 |
Why?
| | Health Services Research | 2 | 2016 | 404 | 0.190 |
Why?
| | Delirium | 1 | 2023 | 92 | 0.190 |
Why?
| | Respiratory Syncytial Viruses | 3 | 2025 | 54 | 0.190 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2025 | 249 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 52 | 0.190 |
Why?
| | Urinary Tract Infections | 1 | 2004 | 188 | 0.190 |
Why?
| | Cytokines | 2 | 2014 | 2085 | 0.190 |
Why?
| | Herpes Zoster Vaccine | 1 | 2024 | 159 | 0.180 |
Why?
| | Immunization, Secondary | 1 | 2022 | 87 | 0.180 |
Why?
| | Veterans Health | 1 | 2023 | 186 | 0.180 |
Why?
| | Metformin | 1 | 2025 | 331 | 0.180 |
Why?
| | Mountaineering | 2 | 2025 | 40 | 0.180 |
Why?
| | Acetaminophen | 1 | 2024 | 268 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
| | Polypharmacy | 1 | 2022 | 85 | 0.180 |
Why?
| | Malawi | 1 | 2021 | 53 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2003 | 245 | 0.180 |
Why?
| | Wounds, Penetrating | 1 | 2022 | 65 | 0.180 |
Why?
| | Immunization Programs | 1 | 2023 | 213 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2023 | 331 | 0.170 |
Why?
| | Health Policy | 1 | 2024 | 388 | 0.170 |
Why?
| | Sentinel Surveillance | 3 | 2025 | 49 | 0.170 |
Why?
| | Abdominal Pain | 1 | 2022 | 145 | 0.170 |
Why?
| | Academic Medical Centers | 4 | 2020 | 512 | 0.170 |
Why?
| | Work | 1 | 2020 | 18 | 0.170 |
Why?
| | Pyridines | 1 | 2024 | 506 | 0.170 |
Why?
| | Rural Population | 3 | 2016 | 563 | 0.170 |
Why?
| | Bayes Theorem | 1 | 2022 | 405 | 0.170 |
Why?
| | Burns | 1 | 2025 | 325 | 0.170 |
Why?
| | Quality of Health Care | 3 | 2010 | 642 | 0.170 |
Why?
| | Telecommunications | 1 | 2020 | 21 | 0.170 |
Why?
| | Hemorrhage | 1 | 2025 | 722 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2025 | 316 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 208 | 0.170 |
Why?
| | Contact Tracing | 1 | 2020 | 27 | 0.170 |
Why?
| | Adrenergic beta-Agonists | 2 | 2012 | 134 | 0.170 |
Why?
| | Neuromuscular Blockade | 2 | 2019 | 31 | 0.170 |
Why?
| | Personnel Turnover | 2 | 2010 | 40 | 0.160 |
Why?
| | Clinical Competence | 3 | 2025 | 1118 | 0.160 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1291 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2024 | 316 | 0.160 |
Why?
| | Abbreviated Injury Scale | 1 | 2019 | 22 | 0.160 |
Why?
| | Chi-Square Distribution | 3 | 2012 | 530 | 0.160 |
Why?
| | Electrocardiography | 1 | 2003 | 629 | 0.160 |
Why?
| | Iraq | 1 | 2019 | 53 | 0.160 |
Why?
| | Physical Therapy Modalities | 1 | 2023 | 308 | 0.160 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1946 | 0.160 |
Why?
| | Pulmonary Embolism | 2 | 2025 | 226 | 0.160 |
Why?
| | Agkistrodon | 1 | 2019 | 5 | 0.160 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2020 | 82 | 0.160 |
Why?
| | Research Design | 2 | 2024 | 1139 | 0.160 |
Why?
| | Infant | 7 | 2019 | 9465 | 0.160 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 318 | 0.160 |
Why?
| | Afghanistan | 1 | 2019 | 71 | 0.160 |
Why?
| | Computer Simulation | 1 | 2024 | 978 | 0.160 |
Why?
| | Symptom Assessment | 1 | 2020 | 128 | 0.160 |
Why?
| | Antivenins | 1 | 2019 | 36 | 0.160 |
Why?
| | Snake Bites | 1 | 2019 | 29 | 0.160 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2019 | 59 | 0.160 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 284 | 0.160 |
Why?
| | Crotalid Venoms | 1 | 2019 | 31 | 0.160 |
Why?
| | Iraq War, 2003-2011 | 1 | 2019 | 127 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2022 | 250 | 0.150 |
Why?
| | Dantrolene | 1 | 2019 | 6 | 0.150 |
Why?
| | Afghan Campaign 2001- | 1 | 2019 | 132 | 0.150 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 2019 | 4 | 0.150 |
Why?
| | Succinylcholine | 1 | 2019 | 4 | 0.150 |
Why?
| | Postoperative Complications | 2 | 2025 | 2654 | 0.150 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2024 | 22 | 0.150 |
Why?
| | Malignant Hyperthermia | 1 | 2019 | 10 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2057 | 0.150 |
Why?
| | Muscle Relaxants, Central | 1 | 2019 | 12 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 5 | 2021 | 565 | 0.150 |
Why?
| | Lactic Acid | 1 | 2020 | 305 | 0.150 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 307 | 0.150 |
Why?
| | Injury Severity Score | 2 | 2022 | 522 | 0.150 |
Why?
| | Needs Assessment | 3 | 2010 | 376 | 0.150 |
Why?
| | Platelet-Rich Plasma | 1 | 2018 | 32 | 0.150 |
Why?
| | Formative Feedback | 1 | 2018 | 28 | 0.150 |
Why?
| | Renal Replacement Therapy | 3 | 2025 | 92 | 0.150 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2019 | 72 | 0.140 |
Why?
| | Consensus | 1 | 2021 | 683 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 102 | 0.140 |
Why?
| | Hospitals, Teaching | 2 | 2011 | 118 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 406 | 0.140 |
Why?
| | Time-to-Treatment | 4 | 2021 | 205 | 0.140 |
Why?
| | Survivors | 1 | 2021 | 493 | 0.140 |
Why?
| | Maryland | 1 | 2017 | 60 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 183 | 0.130 |
Why?
| | Civil Defense | 1 | 2017 | 19 | 0.130 |
Why?
| | Income | 2 | 2008 | 202 | 0.130 |
Why?
| | Infusions, Intravenous | 3 | 2024 | 413 | 0.130 |
Why?
| | Certification | 3 | 2020 | 113 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1153 | 0.130 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2111 | 0.130 |
Why?
| | Fibroblast Growth Factors | 1 | 2018 | 172 | 0.130 |
Why?
| | Assisted Living Facilities | 1 | 2016 | 18 | 0.130 |
Why?
| | Trachea | 3 | 2023 | 237 | 0.130 |
Why?
| | Oxygen Consumption | 1 | 2019 | 696 | 0.130 |
Why?
| | Avalanches | 1 | 2016 | 2 | 0.130 |
Why?
| | Accidental Falls | 2 | 2016 | 196 | 0.130 |
Why?
| | Executive Function | 1 | 2021 | 451 | 0.120 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 216 | 0.120 |
Why?
| | Educational Status | 2 | 2008 | 470 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2020 | 579 | 0.120 |
Why?
| | Advance Directives | 1 | 2016 | 72 | 0.120 |
Why?
| | AIDS Serodiagnosis | 2 | 2012 | 24 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 136 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 847 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 140 | 0.120 |
Why?
| | RNA, Viral | 3 | 2024 | 656 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2031 | 0.120 |
Why?
| | Awareness | 1 | 2015 | 103 | 0.110 |
Why?
| | Data Interpretation, Statistical | 2 | 2024 | 363 | 0.110 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 740 | 0.110 |
Why?
| | Anesthesiology | 1 | 2016 | 87 | 0.110 |
Why?
| | Precision Medicine | 1 | 2018 | 429 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 591 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2014 | 6079 | 0.110 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 234 | 0.110 |
Why?
| | Perioperative Care | 1 | 2016 | 178 | 0.110 |
Why?
| | Frail Elderly | 1 | 2015 | 131 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2014 | 25 | 0.110 |
Why?
| | Feasibility Studies | 3 | 2025 | 956 | 0.110 |
Why?
| | Creatinine | 1 | 2015 | 499 | 0.110 |
Why?
| | Confidence Intervals | 3 | 2010 | 329 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 398 | 0.100 |
Why?
| | Fluvoxamine | 2 | 2023 | 17 | 0.100 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 886 | 0.100 |
Why?
| | Risk | 2 | 2017 | 912 | 0.100 |
Why?
| | Patient-Centered Care | 2 | 2016 | 530 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 243 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 116 | 0.100 |
Why?
| | Neoplasms | 1 | 2008 | 2671 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2022 | 48 | 0.100 |
Why?
| | Physician's Role | 1 | 2014 | 211 | 0.100 |
Why?
| | Headache | 1 | 2013 | 147 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1178 | 0.100 |
Why?
| | Trauma Centers | 2 | 2025 | 421 | 0.100 |
Why?
| | Preventive Health Services | 2 | 2012 | 148 | 0.100 |
Why?
| | Immunization Schedule | 2 | 2025 | 197 | 0.100 |
Why?
| | Hospital Costs | 1 | 2013 | 117 | 0.100 |
Why?
| | Antigens, Viral | 2 | 2024 | 178 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 99 | 0.090 |
Why?
| | Immune System | 1 | 2013 | 177 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1236 | 0.090 |
Why?
| | Oregon | 1 | 2011 | 74 | 0.090 |
Why?
| | Georgia | 1 | 2011 | 86 | 0.090 |
Why?
| | Fractures, Bone | 1 | 2016 | 380 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1238 | 0.090 |
Why?
| | Sex Distribution | 2 | 2013 | 375 | 0.090 |
Why?
| | Massachusetts | 1 | 2011 | 172 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2017 | 1096 | 0.090 |
Why?
| | HIV | 1 | 2012 | 234 | 0.090 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 786 | 0.090 |
Why?
| | ROC Curve | 2 | 2024 | 554 | 0.090 |
Why?
| | Professional Practice Location | 1 | 2010 | 29 | 0.090 |
Why?
| | Specialization | 1 | 2011 | 144 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 431 | 0.090 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2011 | 103 | 0.090 |
Why?
| | Viral Load | 2 | 2023 | 466 | 0.080 |
Why?
| | Health Care Reform | 1 | 2011 | 107 | 0.080 |
Why?
| | Legislation as Topic | 1 | 2010 | 4 | 0.080 |
Why?
| | Delegation, Professional | 1 | 2010 | 1 | 0.080 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 83 | 0.080 |
Why?
| | Emergency Nursing | 1 | 2010 | 22 | 0.080 |
Why?
| | Occupations | 1 | 2010 | 49 | 0.080 |
Why?
| | Medically Underserved Area | 1 | 2010 | 85 | 0.080 |
Why?
| | Mice, Knockout | 1 | 2017 | 3015 | 0.080 |
Why?
| | Allied Health Personnel | 1 | 2010 | 46 | 0.080 |
Why?
| | Albuterol | 1 | 2010 | 110 | 0.080 |
Why?
| | Workload | 1 | 2011 | 167 | 0.080 |
Why?
| | Medical Order Entry Systems | 1 | 2010 | 43 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5757 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1313 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2011 | 224 | 0.080 |
Why?
| | Social Class | 2 | 2009 | 282 | 0.080 |
Why?
| | Altitude | 1 | 2014 | 488 | 0.080 |
Why?
| | Population | 1 | 2009 | 35 | 0.080 |
Why?
| | Motivation | 2 | 2012 | 570 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1704 | 0.080 |
Why?
| | Specialty Boards | 1 | 2009 | 36 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2011 | 283 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2008 | 2 | 0.080 |
Why?
| | Mental Health Services | 1 | 2014 | 421 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2010 | 531 | 0.070 |
Why?
| | Quality of Life | 1 | 2021 | 2892 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2009 | 303 | 0.070 |
Why?
| | Nutritional Status | 1 | 2011 | 350 | 0.070 |
Why?
| | Professional Role | 1 | 2010 | 167 | 0.070 |
Why?
| | Job Satisfaction | 1 | 2010 | 218 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 302 | 0.070 |
Why?
| | Disease Management | 2 | 2011 | 628 | 0.070 |
Why?
| | Self Report | 2 | 2023 | 827 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1066 | 0.070 |
Why?
| | Device Removal | 1 | 2009 | 136 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2012 | 442 | 0.070 |
Why?
| | Nurses | 1 | 2010 | 180 | 0.070 |
Why?
| | Mexican Americans | 1 | 2009 | 120 | 0.070 |
Why?
| | Insulin | 2 | 2009 | 2409 | 0.070 |
Why?
| | Glucocorticoids | 2 | 2023 | 594 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2008 | 307 | 0.070 |
Why?
| | Mental Recall | 2 | 2021 | 202 | 0.070 |
Why?
| | Health Status Indicators | 1 | 2008 | 171 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2014 | 828 | 0.070 |
Why?
| | Morbidity | 1 | 2008 | 324 | 0.070 |
Why?
| | Glucose Tolerance Test | 1 | 2008 | 366 | 0.070 |
Why?
| | Animals | 4 | 2019 | 36940 | 0.070 |
Why?
| | Forecasting | 1 | 2008 | 389 | 0.060 |
Why?
| | Administration, Inhalation | 2 | 2023 | 688 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2014 | 871 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 212 | 0.060 |
Why?
| | RNA | 2 | 2023 | 921 | 0.060 |
Why?
| | Papillomavirus Vaccines | 1 | 2009 | 238 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1266 | 0.060 |
Why?
| | Geography | 1 | 2006 | 200 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 385 | 0.060 |
Why?
| | Picolinic Acids | 1 | 2025 | 9 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 213 | 0.060 |
Why?
| | Self Care | 1 | 2008 | 380 | 0.060 |
Why?
| | Angiotensin I | 1 | 2025 | 7 | 0.060 |
Why?
| | Papillomavirus Infections | 1 | 2009 | 325 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1316 | 0.060 |
Why?
| | Burn Units | 1 | 2025 | 48 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 325 | 0.060 |
Why?
| | Cannula | 1 | 2025 | 20 | 0.060 |
Why?
| | Perioperative Period | 1 | 2025 | 56 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 450 | 0.060 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2024 | 6 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1199 | 0.060 |
Why?
| | Germany | 1 | 2025 | 121 | 0.060 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2024 | 17 | 0.060 |
Why?
| | Androstanols | 1 | 2024 | 18 | 0.060 |
Why?
| | Leukotriene Antagonists | 1 | 2024 | 43 | 0.060 |
Why?
| | Feedback | 1 | 2025 | 173 | 0.060 |
Why?
| | Missouri | 1 | 2004 | 61 | 0.060 |
Why?
| | Pyridazines | 1 | 2024 | 56 | 0.060 |
Why?
| | Lung | 1 | 2017 | 4060 | 0.050 |
Why?
| | Equipment Reuse | 1 | 2024 | 16 | 0.050 |
Why?
| | Prognosis | 2 | 2020 | 4030 | 0.050 |
Why?
| | Qualitative Research | 2 | 2022 | 1386 | 0.050 |
Why?
| | Sample Size | 1 | 2024 | 125 | 0.050 |
Why?
| | Masks | 1 | 2024 | 63 | 0.050 |
Why?
| | Shock | 1 | 2024 | 98 | 0.050 |
Why?
| | Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2024 | 242 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 47 | 0.050 |
Why?
| | Vaccines, Attenuated | 1 | 2024 | 132 | 0.050 |
Why?
| | Long-Term Care | 1 | 2024 | 107 | 0.050 |
Why?
| | Macrolides | 1 | 2003 | 65 | 0.050 |
Why?
| | Calibration | 1 | 2023 | 146 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2008 | 762 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 564 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 288 | 0.050 |
Why?
| | Nucleocapsid | 1 | 2022 | 19 | 0.050 |
Why?
| | Angiotensin II | 1 | 2023 | 99 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2022 | 35 | 0.050 |
Why?
| | Information Dissemination | 1 | 2024 | 218 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 219 | 0.050 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2024 | 268 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 353 | 0.050 |
Why?
| | Immunocompetence | 1 | 2022 | 42 | 0.050 |
Why?
| | Information Systems | 1 | 2022 | 61 | 0.050 |
Why?
| | Syndrome | 1 | 2022 | 358 | 0.050 |
Why?
| | Pulse Therapy, Drug | 1 | 2021 | 7 | 0.050 |
Why?
| | Health Promotion | 2 | 2022 | 741 | 0.040 |
Why?
| | Oligopeptides | 1 | 2023 | 271 | 0.040 |
Why?
| | Pyrimidines | 1 | 2024 | 470 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 73 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2025 | 706 | 0.040 |
Why?
| | Immunization | 1 | 2023 | 411 | 0.040 |
Why?
| | Antimalarials | 1 | 2020 | 31 | 0.040 |
Why?
| | Personnel Staffing and Scheduling | 2 | 2011 | 96 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2022 | 184 | 0.040 |
Why?
| | HIV Infections | 2 | 2012 | 2836 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 194 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 332 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
| | Health Facilities | 1 | 2021 | 84 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2020 | 165 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2021 | 82 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 89 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 669 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2009 | 5131 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 282 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 665 | 0.040 |
Why?
| | Ergocalciferols | 1 | 2019 | 13 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1587 | 0.040 |
Why?
| | Program Evaluation | 1 | 2003 | 898 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2003 | 486 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 916 | 0.040 |
Why?
| | Conscious Sedation | 1 | 2019 | 92 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2024 | 927 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 364 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2025 | 1046 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Informed Consent | 1 | 2018 | 175 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 889 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 98 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 6763 | 0.030 |
Why?
| | Africa | 1 | 2017 | 108 | 0.030 |
Why?
| | Historically Controlled Study | 1 | 2016 | 5 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 327 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2021 | 1023 | 0.030 |
Why?
| | Ghana | 1 | 2015 | 38 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 315 | 0.030 |
Why?
| | Reimbursement, Incentive | 1 | 2015 | 40 | 0.030 |
Why?
| | Cathelicidins | 1 | 2014 | 41 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 362 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2014 | 206 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1397 | 0.030 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2014 | 81 | 0.030 |
Why?
| | Muscle Strength | 1 | 2017 | 317 | 0.030 |
Why?
| | Clinical Coding | 1 | 2013 | 26 | 0.030 |
Why?
| | Internet | 1 | 2017 | 655 | 0.020 |
Why?
| | Bed Occupancy | 1 | 2011 | 16 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 481 | 0.020 |
Why?
| | Domestic Violence | 1 | 2011 | 53 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.020 |
Why?
| | Pamphlets | 1 | 2010 | 23 | 0.020 |
Why?
| | Resource Allocation | 1 | 2010 | 52 | 0.020 |
Why?
| | Demography | 1 | 2010 | 291 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2012 | 251 | 0.020 |
Why?
| | Consumer Health Information | 1 | 2010 | 47 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2844 | 0.020 |
Why?
| | Self Efficacy | 1 | 2012 | 396 | 0.020 |
Why?
| | Psychometrics | 1 | 2012 | 720 | 0.020 |
Why?
| | Teaching | 1 | 2010 | 224 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2012 | 660 | 0.020 |
Why?
| | Research | 1 | 2011 | 451 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 849 | 0.020 |
Why?
| | Anti-Asthmatic Agents | 1 | 2010 | 395 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3284 | 0.010 |
Why?
|
|
Ginde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|